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Abstract
N,N-diethylaminobenzaldehyde (DEAB) is a commonly used “selective” inhibitor of aldehyde 
dehydrogenase isoenzymes in cancer stem cell biology due to its inclusion as a negative control 
compound in the widely utilized Aldefluor assay. Recent evidence has accumulated that DEAB is 
not a selective inhibitory agent when assayed in vitro versus ALDH1, ALDH2 and ALDH3 family 
members. We sought to determine the selectivity of DEAB toward ALDH1A1, ALDH1A2, 
ALDH1A3, ALDH1B1, ALDH1L1, ALDH2, ALDH3A1, ALDH4A1 and ALDH5A1 isoenzymes 
and determine the mechanism by which DEAB exerts its inhibitory action. We found that DEAB 
is an excellent substrate for ALDH3A1, exhibiting a Vmax/KM that exceeds that of its commonly 
used substrate, benzaldehyde. DEAB is also a substrate for ALDH1A1, albeit an exceptionally 
slow one (turnover rate ~0.03 min−1). In contrast, little if any turnover of DEAB was observed 
when incubated with ALDH1A2, ALDH1A3, ALDH1B1, ALDH2 or ALDH5A1. DEAB was 
neither a substrate nor an inhibitor for ALDH1L1 or ALDH4A1. Analysis by enzyme kinetics and 
QTOF mass spectrometry demonstrates that DEAB is an irreversible inhibitor of ALDH1A2 and 
ALDH2 with apparent bimolecular rate constants of 2900 and 86,000 M−1 s−1, respectively. The 
mechanism of inactivation is consistent with the formation of quinoid-like resonance state 
following hydride transfer that is stabilized by local structural features that exist in several of the 
ALDH isoenzymes.
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1. Introduction
Aldehydes are highly reactive compounds that are produced from a variety of endogenous 
and exogenous sources, including cellular metabolites, xenobiotic metabolism and 
environmentally derived pollutants. Although certain aldehydes are critical for biological 
functions, many are cytotoxic and/or carcinogenic due to the highly reactive nature of their 
carbonyl group. Detoxification of aldehydes generally occurs either via oxidation to the 
corresponding carboxylic acid or reduction to the alcohol. The aldehyde dehydrogenase 
(ALDH) superfamily catalyzes the NAD(P)+-dependent oxidation of aldehydes to their 
respective carboxylic acid. The human genome encodes for at least 19 distinct ALDH genes. 
The distribution and expression levels of the various ALDHs is dependent on tissue type, 
with some ALDHs constitutively expressed in most tissues while others demonstrate more 
limited spatial or temporal expression patterns. Mutations in ALDH genes can lead to 
aberrant aldehyde oxidation and have been linked to a number of disorders, including 
Sjögren-Larsson syndrome (ALDH3A2), γ-hydroxybutyric aciduria (ALDH5A1), and type 
II hyperprolinemia (ALDH4A1), and may also contribute to more complex diseases such as 
alcoholism, Alzheimer’s disease, and various cancers [1–3]. The roles of a number of 
ALDH isoenzymes in cancers and the potential for targeting these enzymes for drug 
development has recently been reviewed [4].
The majority of ALDH’s catalyze the irreversible, NAD(P)+-dependent oxidation of an 
aldehyde to its corresponding carboxylic acid, with only ALDH6A1 generating the CoA 
thioester product. There is significant overlap in substrate utilization between some 
isoenzymes, especially those in the ALDH1 and ALDH3 classes. The structure of human 
ALDHs are similar, functioning as either homodimers or homotetramers, with each 
monomer comprised of at least three structural domains; a catalytic domain, a cofactor 
binding domain, and an oligomerization domain [5]. Using the ALDH1A1 sequence as 
reference, Cys303 in the active site performs a nucleophilic attack on the carbonyl carbon of 
the aldehyde, forming a covalent thiohemiacetal intermediate [6]. Hydride transfer to 
NAD(P)+ produces the reduced cofactor and acyl enzyme intermediate, which is hydrolyzed 
by a water molecule activated by Glu269 [7] (Fig. 1). These active site residues are 
conserved in active ALDH isoenzymes. In general, many ALDH enzymes follow an ordered 
mechanism of substrate addition with cofactor binding and release as the initial and final 
steps, but there are differences in the rate-limiting step among the different ALDH enzymes. 
For example, the rate-limiting step for ALDH1A1 is cofactor dissociation [8], the 
deacylation step for ALDH2 [9], and hydride transfer for ALDH3A1 [8–10]. Despite 
similarities in structure and function, the isoenzymes of the ALDH family of proteins have 
evolved to recognize different spectrums of aldehyde substrates due to differences in the size 
and shape of their respective substrate binding sites [5,11]. These differences have permitted 
the development of some selective activators and inhibitors for various isoenzymes as 
therapeutics. For example, disulfiram (commercial: Antabuse) is an inhibitor of both 
ALDH1A1 and ALDH2, and this drug can be used to treat alcoholism [5] and possibly 
cocaine addiction [12]. Alda-1 is a selective activator of ALDH2 and may offer cardiac 
protection following ischemic events by decreasing cytotoxic aldehyde levels [13]. More 
knowledge on the structural and kinetic differences between the ALDH isoenzymes is 
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needed to produce selective and potent small molecule activators and inhibitors for more of 
the ALDH enzymes.
Over 20 years ago, cytosolic ALDH (ALDH1) had been shown to be elevated in 
hematopoietic stem cell (HSC) and could be used for HSC isolation [14,15]. This increase in 
ALDH1 expression had been linked to cyclophosphamide resistance in various leukemia cell 
lines [16]. The first cancer stem cells (CSC) were identified in 1994 for acute myeloid 
leukemia [17] and nearly a decade later, CSCs in solid tumors were discovered [18]. Since 
then, CSC have been identified in a number of cancers and these sub-populations of tumor 
cells have critical roles in tumorigenesis and self-renewal. As with HSC, ALDH’s have been 
identified as possible biomarkers for numerous CSC [19,20]. A commonly used method to 
identify and isolate stem cells is via the Aldefluor Assay (Stemcell Technologies, Inc.) that 
measures ALDH activity in live cells. This assay takes advantage of the conversion of the 
ALDH substrate BODIPY-aminoacetaldehyde (BAAA) to the charged product BOD-IPY-
aminoacetate, which accumulates in cells and enhances their fluorescence. An inhibitor of 
ALDH activity, N,N-diethylaminobenzaldehyde (DEAB), is supplied as a negative control 
for this assay. DEAB was developed as a reversible, competitive inhibitor of ALDH 
enzymes to replace more toxic, irreversible inhibitors like disulfiram. At the time of 
development DEAB was found to be a potent inhibitor of cytosolic ALDH (ALDH1) but not 
mitochondrial ALDH (ALDH2) [21]. Consequently, the Aldefluor Assay was thought to 
identify cellular ALDH1A1 activity, suggesting that the ALDH1A1 isoenzyme was 
responsible for the vast majority of ALDH activity seen in stem cells. However recent 
studies have reported that DEAB inhibits other ALDH isoenzymes and therefore the 
Aldefluor Assay will detect stem cells with other ALDH isoenzyme activity, including 
ALDH1A2, ALDH1A3, and ALDH2 [22,23].
In this report, we used purified recombinant proteins to examine the effect of DEAB on the 
activity of nine ALDH isoenzymes. DEAB was found to be an excellent substrate for 
ALDH3A1. DEAB is also a substrate for ALDH1A1, ALDH1A3, ALDH1B1, ALDH5A1 
but the turnover rates are so slow that it behaves as an inhibitor for more rapidly 
metabolized substrate aldehydes. No appreciable turnover of DEAB was observed with 
either ALDH1A2 or ALDH2, where DEAB behaves as a covalent inhibitor for both 
isoenzymes. DEAB appears neither to be a substrate nor an inhibitor for either ALDH1L1 or 
ALDH4A1. Enzyme kinetics and mass spectrometry were used to develop a mechanism by 
which DEAB exerts its inhibitory effect on these ALDH isoenzymes.
2. Materials and methods
2.1. Materials
Reagents, including acetaldehyde, propionaldehyde, NAD+, and buffers were all purchased 
from Sigma Aldrich unless where otherwise noted.
2.2. ALDH expression and purification
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH2, and ALDH3A1 were produced 
and purified as previously described [24–26]. Production of ALDH1B1 and ALDH1A3 in 
Escherichia coli yielded very little protein, limiting their use. The carboxyl terminus of rat 
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ALDH1L1 was generously provided by Sergey Krupenko in the pRSET expression plasmid. 
The full length cDNA for human ALDH4A1 and ALDH5A1 were generously provided by 
Daria Mochly-Rosen. ALDH4A1 was subcloned into the pET-28a expression plasmid and 
ALDH5A1 into pTrcHis-Topo. ALDH1L1, ALDH4A1, and ALDH5A1 were expressed and 
purified as previously described for ALDH3A1[25] with the following modifications: (1) for 
ALDH1L1 and ALDH5A1 the growth medium contained 100 lg/mL ampicillin, (2) cells 
were lysed via 3 passages through a microfluidizer (DivTech Equipment), and (3) a single 
passage on a nickel-NTA column was used for purification. Purified enzymes were frozen in 
liquid nitrogen and stored at −80 °C in concentrations of 0.5–8.0 mg/mL.
2.3. Wavelength scans to monitor DEAB oxidation
Wavelength scans were performed on the Cary 300 Bio UV-vis spectrophotometer to 
monitor changes in absorbance that could indicate DEAB was acting as a substrate. Scans 
were performed in 1-mL quartz cuvettes and unless where noted contained 500 nM enzyme, 
10 μM DEAB, and 200 μM NAD+ in 50 mM sodium BES pH 7.5 at 25 °C. To confirm 
enzyme activity, a known substrate for each enzyme was added after completion of the scan 
to verify that the enzyme and assay conditions were functional.
2.4. Enzyme kinetics with DEAB as a substrate
To monitor ALDH1A1 and ALDH3A1 activity using DEAB as a substrate, it was necessary 
to determine both what wavelength to monitor and the differential molar extinction 
coefficient between DEAB and NADH at that wavelength. As the reaction time progressed, 
we observed a decrease in absorbance at 360 nm due to loss of DEAB and an increase in 
absorbance at 300 nm and 340 nm due to increases in product formation, 
diethylaminobenzoic acid and NADH, respectfully. The largest molar extinction coefficient 
difference between DEAB and NADH was seen at 360 nm and this wavelength was used for 
these kinetic assays (molar extinction coefficient of 30,160 M−1 cm−1). For ALDH3A1, the 
data was fitted to the substrate inhibition curve using SigmaPlot (StatSys v12.3) and the 
values represent the average of three independent experiments (each n = 3).
2.5. DEAB inhibition and IC50 determination
DEAB inhibition and IC50 curves were assayed spectrophotometrically by monitoring the 
formation of NADH at 340 nm (molar extinction coefficient of 6220 MT−1 cm−1) on a 
Beckman DU-640 or Cary 300 Bio UV-vis spectrophotometer using purified recombinant 
ALDH1A1, ALDH1A2, ALDH1A3, ALDH1B1, ALDH1L1, ALDH2, ALDH4A1, and 
ALDH5A1. All assays were performed at 25 °C Following a two minute incubation of 
enzyme with DEAB and NAD+, the reactions were initiated by adding substrate. With the 
exception of ALDH1L1, ALDH4A1 and ALDH5A1, reactions were. performed in a 
solution containing 100–200 nM enzyme, 200 μM NAD+, 1% DMSO, and 100–200 μM 
propionaldehyde in 50 mM sodium BES pH 7.5. For ALDH4A1, reactions contained 20 
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mM propionaldehyde and 1.5 mM NAD+. For ALDH5A1, reactions contained 2 mM 
propionaldehyde and 1.5 mM NAD+. For ALDH1L1, reactions contained 500 nM enzyme, 
4 mM propionaldehyde and 500 μM NADP+. For enzymes that showed inhibition by DEAB, 
IC50 values for propionaldehyde oxidation were calculated by varying the concentration of 
DEAB from 0 to 20 μ.M. Higher concentrations of DEAB were not used due to interference 
at 340 nm. However there was little to no interference at lower DEAB concentrations. Data 
were fit to the four parameter EC50 equation using SigmaPlot (StatSys v12.3) and the values 
represent the average of three independent experiments (each n = 3).
2.6. Mode of inhibition for ALDH1A1
For ALDH1A1, the mode of inhibition was determined via steady-state kinetics by co-
varying DEAB and acetaldehyde concentrations at fixed concentration of NAD+ and 
assayed spectrophotometrically by monitoring the formation of NADH at 340 nm (molar 
extinction coefficient of 6220 M−1 cm−1) on a Beckman DU-640. Reactions contained 150 
nM ALDH1A1, 1% DMSO, 100–800 μM acetaldehyde (Km = 180 μM), 0–25 nM DEAB, 
and 500 μM NAD+ (Km = 55 μM) in 50 mM sodium BES, pH 7.5 at 25 °C. All data were fit 
to competitive, noncompetitive, uncompetitive, and mixed inhibition models using tight 
binding inhibition programs in SigmaPlot (StatSys v12.3). The appropriate model was 
selected through analysis of goodness-of-fit and the residuals of those fits. The values 
represent the average of three independent experiments (each n = 3) using at least two 
protein preps.
2.7. Kinetics of irreversible inhibition for ALDH1A2 and ALDH2
For ALDH1A2, solutions containing 100 nM enzyme, 0.1–2.0 μM DEAB, and 1.5 mM 
NAD+ in 50 mM sodium BES, pH 7.5 were incubated at 25 °C. For ALDH2, solutions 
containing 100 nM enzyme, 100–400 nM DEAB, and 1.5 mM NAD+ in 50 mM sodium 
BES, pH 7.5 were incubated at 25 °C. At the designated time point, the remaining enzyme 
activity was determined spectrophotometrically by adding a saturating amount of 
propionaldehyde (1.0 mM) and monitoring NADH production at 340 nm on a Beckman 
DU-640. This concentration of propionaldehyde is sufficient to prevent any additional 
DEAB-dependent inactivation of both ALDH1A2 and ALDH2, thereby obviating the need 
for sample dilution prior to assay. The apparent bimolecular rate constants for inactivation 
were determined using traditional linear analysis of covalent enzyme inactivation [27]:
The values represent the average ± SE of three independent experiments, with ALDH1A2 at 
n = 2 and ALDH2 at n = 3. To assess whether treatment of DEAB leads to irreversible 
covalent modification of ALDH2 and ALDH1A2, 10 μM of each enzyme was pre-incubated 
with 100 μM DEAB in the presence or absence of 1 mM NAD+ for 30 min (1 mL total 
reaction volume). Samples (20μL) were removed for enzyme activity determination in 1 mL 
assays. The samples were then dialyzed separately against 4 L of 30 mM BES, pH 7.5 for 
four hours. The dialysis buffer used for the NAD+-containing incubation also contained 1 
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mM NAD+. Control reactions contained 10 μM ALDH2 or ALDH1A2 were identically 
treated to a 30 min incubation in the absence of DEAB and dialyzed in separate 4 L 
containers. Dehydrogenase activity was measured from 20 μL aliquots before and after 
dialysis using 1.5 mM NAD+ and 1 mM propionaldehyde in a 1 mL assay volume. The post-
dialysis measurements were normalized to control by adjusting for the concentration of 
protein in each sample.
2.8. Mass spectrometry
Complexes for analysis by mass spectrometry were formed from 2.5–10.0 μM of the ALDH 
isoenzyme with 10 μM DEAB with or without 100–500 μM NAD+ and incubated for 1 h at 
room temperature in 10 mM HEPES, pH 7.5. Samples (0.5–5 μL) were injected using an 
Agilent 1200SL HPLC with a low rate of 0.3 mL/min consisting of 70% H2O and 30% 
acetonitrile with 0.1% formic acid into an Agilent 6520 quadrupole-time of flight (Q-TOF) 
mass spectrometer operating in TOF mode. The spectra were extracted and deconvoluted 
using MassHunter and Bioconfirm software.
3. Results
DEAB shows a characteristic absorbance peak near 360 nm, while the oxidized product 
N,N-diethylaminobenzoic acid shows an absorbance peak at 300 nm (Fig. 2). If DEAB is a 
substrate for members of the aldehyde dehydrogenase, it should be possible to monitor the 
decrease in absorbance at 360 nm and an increase in absorbance at 300 nm. The changes 
near these absorbance bands will be convolution of the decrease of DEAB, increase of the 
product acid and the increase in NADH due to its less prominent absorption band at 340 nm 
(6220 M−1 cm−1). The extinction coefficient for DEAB at 360 nm is 34,380 M−1 cm−1 and 
the extinction coefficient for diethylaminobenzoic acid at 300 nm is 20,370 MT−1 cm−1. In 
addition, there are some changes in the absorbance features over time, even in the absence of 
enzyme (Fig. 3). However, in the presence of five of the nine ALDH enzymes tested, there 
is an observable increase in the rate of oxidation, indicating that DEAB can act as a substrate 
for these isoenzymes. For incubations between DEAB and ALDH1A1, the scan shows a loss 
in absorbance at 360 nm, indicating disappearance of DEAB, plus an increase in absorbance 
at 300 nm, corresponding to the appearance of the carboxylic acid product (Fig. 4A). With 
500 nM ALDH1A1, oxidation of a large percentage of the 10 μM DEAB had occurred in 3.5 
h. The strong absorption of DEAB at 360 nm partially masks NADH formation at 340 nm. 
Monitoring the change in absorbance at 360 nm (molar extinction coefficient of 30,160 
MT−1 cm−1), we calculated the ALDH1A1 turnover rate of DEAB at 0.028 ± 0.002 per min. 
DEAB was turned over very rapidly by ALDH3A1 using only 25 nM enzyme, indicating 
that it is a very good substrate for this isoenzyme (Fig. 4B). However, with ALDH2 there 
was only a moderate change in the traces after 4 h, similar to DEAB incubated in the 
absence of enzyme (Fig. 4C). Wavelength scans for ALDH1A2 and ALDH4A1 were similar 
to ALDH2, suggesting that DEAB is either an extremely slow substrate or is not turned over 
by these three isoenzymes. DEAB is a very slow substrate for ALDH1B1 (Fig. 4D) and the 
wavelength scans for ALDH1A3 and ALDH5A1 were similar to ALDH1B1. For all nine 
isoenzyme scans, there was no change in absorbance noted from 400 to 600 nm, and even 
after a 16 h scan, the enzymes were still active and capable of propionaldehyde oxidation.
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Wavelength scans indicated that DEAB was turned over by ALDH3A1 much more rapidly 
than by the other ALDH isoenzymes tested. Kinetic analysis of the saturation profile for 
DEAB was best fit to the Michaelis–Menton equation modified for substrate inhibition, 
producing a Km of 5.6 ± 0.7 μM and a Kis of 38.8 ± 3.3 μM (Fig. 5). For comparison, the Km 
of the commonly used substrate benzaldehyde is 50-fold higher at 280 μM (Table 1).
Although DEAB is a substrate for ALDH1A1, ALDH1A3, ALDH1B1, and ALDH5A1, it is 
turned over at such a slow rate it is effectively an inhibitor for the oxidation of other 
substrate aldehydes such as acetaldehyde and propionaldehyde. DEAB inhibited six of nine 
ALDH isoenzymes tested and all had IC50 values less than 15 μM (Table 2). Under the 
conditions of the experiments, it was a more potent inhibitor for ALDH1A1 (IC50 = 57 ± 5 
nM) compared to the other isoenzymes (Fig. 6A). DEAB displayed a competitive mode of 
inhibition toward ALDH1A1 with respect to varied acetaldehyde with a Ki of 9.8 ± 3.1 nM 
(Fig. 6B). During IC50 calculations for ALDH2, it was discovered that the IC50 values were 
dependent on order of addition and incubation times, no inhibition was observed up to 50 
μM (maximum concentration used) when the reaction was initiated by adding enzyme, but 
160 ± 30 nM following a two minute pre-incubation of enzyme with DEAB and NAD+ and 
initiating with propionaldehyde. Under these conditions, for both enzymes the 
propionaldehyde concentration was at least 20-fold greater than Km, but saturation with 
propionaldehyde did not lead to recovery of full enzymatic activity, suggesting that DEAB 
is covalently modifying ALDH2. ALDH1A2 behaved in a similar manner. When treated as 
a covalent irreversible inhibitor, the apparent bimolecular rate constants for inhibition of 
ALDH1A2 and ALDH2 were 2900 ±160 M−1 s−1 and 85,800 ± 4200 M−1 s−1, respectively 
(Fig. 7).
Mass spectrometry was used to determine whether DEAB was covalently binding to the 
ALDH enzymes. Quadrupole TOF MS of ALDH1A1, ALDH1A2, ALDH1B1, and ALDH2 
confirmed that there was an increase in mass of 175 Da, corresponding to DEAB binding 
with the loss of two protons. With 5 μM ALDH2 alone (Fig. 8A) or incubated with 10 μM 
DEAB without NAD+ (Fig. 8B) there was a major peak at 54,445 plus a much smaller peak 
at 54,357, a difference of 87 Da likely corresponding to loss of the N-terminal serine during 
protein production. ALDH2 incubated with both DEAB and 500 μM NAD+ resulted in a 
major peak at 54,620 and much smaller peaks at 54,533, 54,445, and 54,357 (Fig. 8C). The 
peaks at 54,620 and 54,533 represent a shift of 176 Da from 54,445 and 54,357, respectfully, 
and correspond to DEAB binding to the two major ALDH2 species present in the sample. A 
similar shift was seen using 2.5 μM MALDH1B1,10 μM DEAB, and 500 μM NAD+ (data 
not shown). ALDH1B1 alone or incubated with DEAB yielded a major peak at 56,592 and a 
much smaller peak at 57,200, this latter peak may represent an enzyme species modified by 
two glutathione molecules. However, incubation of ALDH1B1, DEAB, and NAD+ shifted 
the major peak to 56,768 with much smaller peaks at 56,592, corresponding to unmodified 
protein, and 57,375. Both the ALDH2 and ALDH1B1 data indicate that NAD+ must be 
present for DEAB to modify the enzyme in a manner detectable by mass spectrometry. After 
a one hour incubation with a 2- to 4-fold molar excess of DEAB, most of the enzyme 
present had been modified. DEAB also covalently modifies ALDH1A1 in the presence of 
NAD+ but is not complete (Fig. 9). These shifts in peaks corresponding to DEAB binding 
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with a loss of 2 protons are similar to what is seen with ALDH1A1 and a known substrate 
benzaldehyde. Using 5 μM ALDH1A1, 1.5 mM NAD+, and 2.5 mM benzaldehyde, there is 
a 104 Da shift corresponding to the substrate binding to ALDH1A1 with the loss of 2 
hydrogens in the presence of enzyme, cofactor, and substrate (Fig. 10). Association of 
DEAB with ALDH1A1, ALDH1B1, and ALDH2 was dependent on NAD+, but the 
requirement for NAD+ was not absolute for ALDH1A2. Using 5.0 μM ALDH1A2, 10 μM 
DEAB, and 500 μM NAD+, enzyme alone yielded a major peak at 56,592 and a much 
smaller peak at 56,830 (Fig. 11A). When ALDH1A2 is incubated with DEAB, the major 
peak is still at 56,592 but a large peak is also seen at 56,768, corresponding to DEAB 
binding to approximately one-third of the ALDH1A2 present, with smaller peaks at 56,830 
and 57,007 (Fig. 11B). Following incubation of ALDH1A2, DEAB, and NAD+, the major 
peak was seen at 56,768, with smaller peaks at 56,592 and 57,006 (Fig. 11C). These results 
imply that DEAB may bind to ALDH1A2 independent of the presence of coenzyme. 
However, it may be possible that oxidized coenzyme co-purifies with ALDH1A2. To 
determine whether NAD+ is present from the ALDH1A2 protein purification, 500 μM 
propionaldehyde was added to 18 μM ALDH1A2 without additional NAD+ and monitored 
for 15 min. There was no change at 340 nm, indicating that NADH is not being produced in 
this reaction. This suggests that NAD+ is, at a minimum, not present at the molar ratio levels 
suggested by mass spectrometry, since reactions using only 5 μM NAD+ produce an 
observable change at 340 nm. To confirm covalent modification and investigate the 
requirement for NAD+ to inactivate ALDH2 and ALDH1A2, the enzymes were incubated in 
the presence of DEAB with and without NAD+ and then dialyzed for 4 h against a 4000-fold 
excess of buffer. Relative to control samples incubated in the absence of DEAB, neither the 
ALDH2 nor the ALDH1A2 samples regained enzymatic activity when DEAB and NAD+ 
were present in the incubation, consistent with irreversible, covalent modification (Fig. 12). 
In contrast to the level of inactivation observed with DEAB and NAD+, incubation of 
enzyme plus DEAB alone, resulted in only partial inactivation of both ALDH2 and 
ALDH1A2. Dialysis had no impact on the level of inactivation for ALDH2, but the 
ALDH1A2sample recovered 75%ofthe control activity, suggesting the latter modification is, 
in part, reversible (Fig. 12).
4. Discussion
A number of isoenzymes in the aldehyde dehydrogenase superfamily have been linked to 
both normal and cancer stem cells. The Aldefluor assay relies on their aldehyde oxidation 
abilities to identify and segregate stem cells with high levels of ALDH activity. Inhibition of 
ALDHs by DEAB, an aldehyde, is used as a control. The concept of substrates as inhibitors 
is not new. A number of organophosphorus compounds are esters that inhibit cholinesterase 
by acetylating the enzyme in a process similar to its normal substrate acetylcholine. As 
discussed by Aldridge, the only difference between a substrate (acetylcholine) and an 
inhibitor (i.e. dimethylphosphates) is the rate of reaction [28]. In this paper, we have shown 
that DEAB is both a substrate and an inhibitor for certain ALDH isoenzymes and that the 
rate of reaction, namely hydrolysis, determines whether the compound behaves as a classic 
substrate (ALDH3A1), as a covalent inhibitor, (ALDH2 and ALDH1A2), or as an 
intermediate between substrate and inhibitor (ALDH1A1, ALDH1A3, ALDH1B1, and 
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ALDH5A1). We propose that differences in residues at the substrate binding sites of the 
isoenzymes are capable of stabilizing the acyl-enzyme intermediate to varying degrees. In 
ALDH3A1, little to no stabilization occurs and DEAB is quickly turned over, resulting in a 
low micromolar KM. For ALDH2 and ALDH1A2, the acyl-enzyme is very stable and little 
observable turnover occurs, thus mimicking a covalent inhibitor. However we do believe 
these two enzymes are capable of eventually oxidizing DEAB at an extremely low rate. We 
propose that structural features within their respective active sites are capable of stabilizing a 
resonance structure intermediate (Fig. 13).
Based on the kinetic and mass spectrometry data we propose that DEAB functions as a 
substrate for all enzymes through the hydride transfer step, but that the acyl-enzyme 
intermediate is slowed for hydrolysis by a resonance structure available to the thioester 
intermediate due to the lone pair of electrons on the para-diethylamino substituent (Fig. 13). 
The addition of the lone pair into the aromatic ring resonance promotes the formation of a 
quinoid-like structure where the extra electrons now reside on the carbonyl oxygen atom 
where it is stabilized by the oxy-anion hole comprised of the peptide amide nitrogen of the 
catalytic nucleophile and the side chain amide nitrogen of the residue equivalent to Asn169 
in ALDH2. The intermediate stabilized in this manner makes the carbonyl carbon less 
susceptible to attack by a hydroxyl ion. The extent that this resonance structure forms and 
the duration of its stabilization would appear to differ between the various isoenzymes with 
which DEAB forms productive interactions. Mass spectroscopy data shows no evidence of 
additional hydrolytic breakdown of the aromatic imine compound during the timeframe of 
the MS experiment.
The fact that DEAB is an excellent substrate for ALDH3A1 is not altogether surprising, 
since the enzyme is known to prefer aromatic substrates over linear aliphatic substrates 
[29,30]. It is interesting that even for ALDH3A1, the kcat is lower for DEAB than for 
benzaldehyde by an order of magnitude, making DEAB, by definition, a slow substrate. 
Thus, only the fact that the KM for DEAB is ~50-fold lower than for benzaldehyde places 
the catalytic efficiency for DEAB amongst the best for known substrates. For acetaldehyde 
and benzaldehyde, hydride transfer is known to be rate-limiting for catalysis in ALDH3A1 
[10], implying that either hydride transfer is 11-fold slower for DEAB or another step has 
become rate-limiting. We suggest that acyl-enzyme hydrolysis has become rate-limiting due 
to the potential for resonance stabilization of the acyl-enzyme intermediate and the fact that 
the electronic properties of DEAB should promote easier extraction of the hydride ion from 
the thiohemiacetal. Measurements of the isotope effects or stopped-flow analyses will be 
necessary to distinguish between these or other mechanistic possibilities for ALDH3A1. 
However, it is clear that the acyl-enzyme intermediate formed between ALDH3A1 and 
DEAB is the shortest lived of any ALDH acyl-enzyme species by at least 3-orders of 
magnitude. The short life-time may be influenced by the curved nature of the enzyme’s 
substrate-binding site [26], which likely distorts the planar conformations required to 
maintain the aromatic quinoid resonance state.
DEAB is a good to excellent inhibitor for all but three of the ALDH isoenzymes examined, 
with IC50 values ranging between 57 nM to 13 μM. The most potent inhibition by DEAB is 
toward ALDH1A1, followed by ALDH2, ALDH1A2, ALDH1B1, ALDH1A3 and 
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ALDH5A1. However, the relative order for enzymatic turnover follows the order 
ALDH1A1 > ALDH1B1, ALDH1A3, ALDH5A1 > ALDH1A2, ALDH2. Thus, it would 
seem that the two properties of DEAB, inhibition vs substrate, are not directly correlated. 
DEAB demonstrates the most potent inhibition for ALDH1A1 with an IC50 of 57 nM and 
competitive mode of inhibition toward acetaldehyde with a Ki of 10 nM. Consequently, 
despite the low turnover of this complex (0.028 min−1), these properties give rise to a 
pseudo-bimolecular rate constant of ~47,000 M−1 s−1, which is within a factor of two for the 
value obtained for DEAB inactivation of ALDH2 at 86,000 M−1 s−1. Both these values 
imply a rapid association between enzyme and DEAB. ALDH1A2 is 20- to 30-fold slower, 
correlating with its 10- to 100-fold higher IC50 values. The interactions between DEAB and 
ALDH1A3 or ALDH1B1 are similar to ALDH1A2, although these enzymes do show very 
slow turnover of their respective enzyme-DEAB complexes.
An inspection of the respective active site structures fails to identify consistent differences in 
residues lining the substrate sites that correlate with all the features of DEAB interactions. 
ALDH1A1 is the most wide open substrate binding site which is best described as a 
flattened funnel shape, due to Gly substitutions at both positions 125 and 458 and Val at 
positions 174 and 460 [26]. The ALDH1A2, ALDH1A3 and ALDH1B1enzymes have 
substrate sites more similar to the cylindrical site in ALDH2 [26] and perhaps these sites 
better constrain the aromatic system to remain planar, thereby increasing the residency time 
of the quinoid intermediate and slowing hydrolysis. The active site structure of ALDH5A1 
(PDB code 2W8R, [31]) is next most similar to ALDH2, but its low reactivity toward DEAB 
may be due to the presence of two characteristic arginine residues near the middle and outer 
regions of the substrate site, R213 and R334. Presumably, the binding site in ALDH5A1 
does not stabilize the acyl-enzyme intermediate sufficiently to prevent turnover.
That DEAB fails to inhibit ALDH1L1 and ALDH4A1, suggests that elements of the 
substrate binding site in these isoenzymes are incompatible with forming a productive 
thiohemiacetal intermediate with DEAB in the first place. ALDH1L1 has a very narrow 
active site surrounding the catalytic nucleophile which may exclude aromatic substrates 
from its active site. In agreement with this observation, aromatic aldehydes are poor 
substrates for ALDH1L1. In the case of ALDH4A1 (PDB code 4LH2, [32]), it is the outer 
region of the substrate binding site that is narrowed which may prevent DEAB association.
5. Conclusions
DEAB possesses all the characteristics of a substrate for many ALDH isoenzymes, 
especially ALDH3A1. However, its particular electronic properties give rise to a stalled 
acyl-enzyme intermediate in ALDH isoenzymes that can stabilize its electronic resonance 
structure, making DEAB a mechanism-based inhibitor for ALDH2 and ALDH1A2, a very 
slow substrate for ALDH1A3, ALDH1B1 and ALDH5A1, and finally a slow substrate for 
ALDH1A1. In contrast, DEAB is neither a substrate nor an inhibitor for ALDH1L1 or 
ALDH4A1. The broad and varied nature of the interaction between DEAB and ALDH 
isoenzyme suggests that its use as an inhibitor or competitive substrate in the Aldefluor 
assay, should be interpreted with caution with respect to which particular ALDH isoenzymes 
contribute to the observed signal in the flow-cytometry assay.
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Fig. 1. 
Mechanism of aldehyde oxidation based on ALDH2 active site residues: (1) catalytic 
cysteine (Cys302) activated by water-mediated proton abstraction by glutamate (Glu268), (2) 
nucleophilic attack on the carbonyl carbon of the aldehyde by Cys302, (3) formation of a 
tetrahedral thiohemiacetal intermediate and hydride transfer to the cofactor NAD(P)+, (4) 
hydrolysis of thioester intermediate and release of carboxylic acid product and reduced 
cofactor, and (5) regeneration of activated enzyme by binding cofactor.
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Fig. 2. 
Absorption characteristics of diethylaminobenzaldehyde and diethylaminobenzoic acid. The 
substrate and product of the reaction absorb at different wavelengths, allowing the reaction 
to be monitored. For both diethylaminobenzaldehyde and diethylaminobenzoic acid, 10 μM 
of compound was used. The green trace represents the buffer BES and 100 μM NAD+. (For 
interpretation of the references to color in this figure legend, the reader is referred to the web 
version of this article.)
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Fig. 3. 
Oxidation of DEAB in the absence of enzyme. Wavelength scans indicate that DEAB 
oxidizes to its acid at a slow rate in a 50 mM Na+-BES pH 7.5 at 25 °C, the buffer 
conditions used for wavelength scn assays with the enzymes. No NAD+ is present. The 
green line represents a water trace while the magenta line is BES alone (no DEAB). Over 
time, there was a decrease at 360 nm corresponding to DEAB and an increase at 300 nm 
corresponding to diethylaminobenzaldehyde. (For interpretation of the references to color in 
this figure legend, the reader is referred to the web version of this article.)
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Fig. 4. 
Wavelength scans of ALDH1A1, ALDH3A1, ALDH2, and ALDH1B1 with DEAB. For 
ALDH1A1 and ALDH2, and ALDH1B1 reactions containing 500 nM enzyme, 200 μM 
NAD+, and 10 μM DEAB were monitored from 200–600 nm. (A) For ALDH1A1, a gradual 
decrease at 360 nm and increase at 300 nm is seen, corresponding to substrate lose and 
product formation, respectfully. (B) For ALDH3A1, the reaction contained 25 nM enzyme, 
200 μM NAD+, and 10 μM DEAB and rapid DEAB oxidation occurs. (C) For ALDH2, there 
is little change in the spectrographic trace after 4 h. (D) ALDH1B1 had more DEAB 
oxidation then ALDH2 but turnover was still low. For all reactions, no absorption changes 
were seen above approximately 400 nm.
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Fig. 5. 
Substrate saturation curve for ALDH3A1 with DEAB as a substrate. This curve represents 
one of three experiments, each n = 3, it to the substrate inhibition equation.
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Fig. 6. 
Characterization of ALDH1A1 with DEAB (A) IC50 curve of DEAB with 150 nM 
ALDH1A1. (B) Lineweaver–Burk plot to determine the Ki of DEAB for ALDH1A1. Each 
plot represents one of three experiments, with each point representing the average ± SE of 
three independent readings.
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Fig. 7. 
Time dependent inhibition of human (A) ALDH1A2 and (B) ALDH2 with DEAB. For each 
enzyme, the primary plots show the ln (percentage activity) vs time. The slopes were used to 
generate the secondary plots, −k′ versus DEAB concentration. The bimolecular rate constant 
for inhibition for each enzyme was calculated from the slope of the line of the secondary 
plot. Each plot represents one of three experiments, with ALDH1A2 at n = 2 and ALDH2 at 
n = 3.
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Fig. 8. 
Modification of human ALDH2 with DEAB. Deconvoluted spectrum of (A) ALDH2, (B) 
ALDH2 incubated with 2-fold molar excess of DEAB, and (C) ALDH2 incubated with 2-
fold molar excess of DEAB and saturating NAD+.
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Fig. 9. 
Modification of human ALDH1A1 with DEAB. Deconvoluted spectrum of (A) ALDH1A1, 
(B) ALDH1A1 incubated with 10-fold molar excess of DEAB, and (C) ALDH1A1 
incubated with 10-fold molar excess of DEAB and saturating NAD+.
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Fig. 10. 
Modification of human ALDH1A1 with benzaldehyde. Deconvoluted spectrum of (A) 
ALDH1A1, (B) ALDH1A1 incubated with 500-fold molar excess of benzaldehyde, and (C) 
ALDH1A1 incubated with 500-fold molar excess of benzaldehyde and saturating NAD+.
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Fig. 11. 
Modification of human ALDH1A2 with DEAB. Deconvoluted spectrum of (A) ALDH1A2, 
(B) ALDH1A2 incubated with 2-fold molar excess of DEAB, and (C) ALDH1A2 incubated 
with 2-fold molar excess of DEAB and saturating NAD+.
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Fig. 12. 
Effects of Dialysis on DEAB-induced inhibition. ALDH1A2 and ALDH2 were pre-
incubated for 30 min with DEAB in the presence or absence of NAD+. Solutions were 
dialyzed for 4 h against a 4000-fold excess of buffer and the activity post-dialysis compared 
to the levels prior to dialysis. ALDH2 prior to dialysis (■), ALDH2 following dialysis (▧), 
ALDH1A2 prior to dialysis (□), ALDH1A2 following dialysis (▤).
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Fig. 13. 
Proposed mechanism of action of DEAB on ALDH enzymes.
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Table 1
Kinetic parameters for ALDH3A1 oxidation of DEAB.
Substrate KM (mM) kcat (min−1) kcat/KM
Benzaldehyde 280 ± 20 1400 ± 60 4.9 ± 0.3
DEAB  5.6 ± 0.7   130 ± 20  24 ± 1
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Table 2
Effect of DEAB on ALDH isoenzymes.
Substrate IC50 (μM) mean/SEM Comments
ALDH1A1 Yes 0.057 ±0.005 Competitive tight inhibition Ki = 10 ± 3 nM
ALDH1A2 No     1.2 ± 0.1 Covalent inhibitorapparent bimolecular rate 2900 ± 160 M−1 s−1
ALDH1A3 Yes (slow)     3.0 ± 0.3
ALDH1B1 Yes (slow)     1.2 ± 0.1
ALDH1L1 No NI*
ALDH2 No   0.16 ± 0.03 Covalent inhibitor apparent bimolecular rate 86,000 ± 4200 M−1 s−1
ALDH3A1 Yes NA# Km = 5.6 μM
ALDH4A1 No NI*
ALDH5A1 Yes (slow)      13 ± 0.5
*NI denotes no detectable inhibition.
#NA denotes not applicable as an inhibitor.
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